Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA
Year: 2022
Type: article
Source: Clinical Drug Investigation
Institution: Florida Agricultural and Mechanical University
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: closed
OpenAlex ID: W4281552441
